Search

Your search keyword '"Zaja, F."' showing total 8 results
Start Over Author "Zaja, F." Journal annals of hematology
8 results on '"Zaja, F."'

1. Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography

Author

Puccini, B ., Nassi, L., Minoia, C., Volpetti, S., Ciancia, R., Riccomagno, P. C., Di Rocco, A., Mulè, A., Toldo, C., Sassone, M. C., Guariglia, R., Filì, C., Finolezzi, E., Falorio, S., Zanon, S., Furlan, A., Doa, G., Zaja, F., and on behalf of the Fondazione Italiana Linfomi Postgraduate Master course

Published
2017
Full Text
View/download PDF

5. Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography

Author

A. Di Rocco, R. Guariglia, S. Falorio, P. C. Riccomagno, G. Doa, Benedetta Puccini, Erica Finolezzi, Rosanna Ciancia, A. Mulè, C. Filì, C. Toldo, S. Zanon, Stefano Volpetti, Carla Minoia, Francesco Zaja, A. Furlan, Marianna Sassone, Luca Nassi, Puccini, B., Nassi, L., Minoia, C., Volpetti, S., Ciancia, R., Riccomagno, P. C., Di Rocco, A., Mulè, A., Toldo, C., Sassone, M. C., Guariglia, R., Filì, C., Finolezzi, E., Falorio, S., Zanon, S., Furlan, A., Doa, G., and Zaja, F.

Subjects
Male, Staging, Biopsy, Bone marrow biopsy, Computed tomography, Hodgkin’s lymphoma, Positron emission tomography, Adolescent, Adult, Aged, 80 and over, Bone Marrow, Bone Marrow Examination, Female, Hodgkin Disease, Humans, Middle Aged, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Young Adult, Hematology, 0302 clinical medicine, Retrospective Studie, Positive predicative value, Stage (cooking), Radiation treatment planning, Hodgkinâ s lymphoma, Aged, 80 and over, medicine.diagnostic_test, General Medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Radiology, Human, medicine.medical_specialty, Reproducibility of Result, 03 medical and health sciences, medicine, business.industry, medicine.disease, Hodgkin's lymphoma, Lymphoma, Bone marrow, Nuclear medicine, business, Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography, 030215 immunology
Abstract

Several studies suggested that staging bone marrow biopsy (BMB) could be omitted in patients with classical Hodgkin's lymphoma (cHL) when a positron emission tomography/computed tomography (PET/CT) is performed at baseline.To address the concordance between BMB and PET/CT in the detection of bone marrow involvement (BMI) and the BMB role in determining the Ann Arbor stage, we retrospectively collected data on 1244 consecutive patients with cHL diagnosed from January 2007 to December 2013. One thousand eighty-five patients who had undergone both BMB and PET/CT were analyzed, comparing the Ann Arbor stage assessed with PET/CT only to that resulting from PET/CT combined with BMB.One hundred sixty-nine patients (16%) showed at least one focal skeletal lesion (FSL) at PET/CT evaluation. Only 55 patients had a positive BMB (5.1%); 34 of them presented at least one FSL at PET/CT. To the contrary, 895 out of 1030 patients with a negative BMB did not show any FSL (86.9%). Positive and negative predictive values of PET/CT for BMI were 20 and 98%, respectively; sensitivity and specificity were 62 and 87%, respectively. Fifty-four out of 55 patients with a positive BMB could have been evaluated as an advanced stage just after PET/CT; only one patient (0.1%) would have been differently treated without BMB.Our data showed a very high negative predictive value of PET/CT for BMI and a negligible influence of BMB on treatment planning, strengthening the recent indications that BMB could be safely omitted in cHL patients staged with PET/CT.

Published
2016

6. Meningeal and cerebral involvement in multiple myeloma patients

Author

Francesca Patriarca, Renato Fanin, Anna Scalise, Federico Silvestri, Francesco Zaja, Alessandra Sperotto, Gian Luigi Gigli, Patriarca, Francesca, Zaja, Francesco, Silvestri, F, Sperotto, A, Scalise, A, Gigli, Gian Luigi, Fanin, Renato, Patriarca, F, Zaja, F, Gigli, G, and Fanin, R.

Subjects
Pathology, Immunoglobulin kappa-Chain, medicine.medical_treatment, Antineoplastic Agent, Cerebrospinal Fluid Protein, Glucocorticoid, Cerebrospinal fluid, Fatal Outcome, Multiple myeloma, Recurrence, High-dose therapy, Myelomatous meningiti, Cerebrospinal Fluid, Cerebral plasmacytoma, Myelomatous meningitis, Aged, Antineoplastic Agents, Brain Neoplasms, Cerebrospinal Fluid Proteins, Combined Modality Therapy, Female, Glucocorticoids, Humans, Immunoglobulin Light Chains, Immunoglobulin kappa-Chains, Magnetic Resonance Imaging, Meningitis, Middle Aged, Multiple Myeloma, Plasmacytoma, Prednisone, Radiotherapy, Remission Induction, Hematology, General Medicine, Human, medicine.drug, medicine.medical_specialty, Brain Neoplasm, Central nervous system disease, medicine, Chemotherapy, business.industry, Induction chemotherapy, medicine.disease, Meningiti, Cytarabine, Immunoglobulin Light Chain, business
Abstract

Cerebral involvement is an unusual complication in multiple myeloma: herein four patients who presented myelomatous meningitis with multiple intraparenchymal lesions or a localized cerebral plasmacytoma are described. Two of these patients relapsed with meningeal involvement and a very limited disease outside the central nervous system after an initial complete remission obtained with induction chemotherapy. In the other two cases, the cerebral tumor appeared during first-line treatment. Cytological examination of the cerebrospinal fluid and magnetic resonance were essential for diagnosis. Different modalities of treatment were used, including intrathecal chemotherapy, cranial irradiation, and systemic chemotherapy with high-dose methotrexate and cytarabine, achieving improvement of neurological symptoms in three of four patients.

Published
2001

7. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.

Author

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, and Mian M

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prednisone administration & dosage, Retrospective Studies, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bendamustine Hydrochloride administration & dosage, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin drug therapy, Rituximab administration & dosage
Abstract

The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still highly debated. Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile. Utilizing a retrospective analysis, we compared the efficacy and safety of both regimens in clinical practice. From November 1995 to January 2014, 263 LG-NHL patients treated with either R-B or R-CHOP were retrospectively assessed in seven European cancer centers. Ninety patients were treated with R-B and 173 with R-CHOP. Overall response rate was 94 and 92 % for the R-B and the R-CHOP group, respectively. The percentage of complete response was similar for both groups (63 vs. 66 % with R-B and R-CHOP, respectively; p = 0.8). R-B was better tolerated and less toxic than R-CHOP. The median follow-up was 6.8 and 5.9 years for the R-CHOP and the R-B group, respectively. Overall, no difference in progression-free survival (PFS) (108 vs. 110 months; p = 0.1) was observed in the R-B group compared to the R-CHOP cohort. Nevertheless, R-B significantly prolonged PFS in FL patients (152 and 132 months in the R-B and R-CHOP group, respectively; p = 0.05). However, this result was not verified in multivariate analysis probably due to the limits of the present study. We confirm that the R-B regimen administered in patients with LG-NHL is an effective and less toxic therapeutic option than R-CHOP in clinical practice.

Published
2016
Full Text
View/download PDF

8. Bendamustine salvage therapy for T cell neoplasms.

Author

Zaja F, Baldini L, Ferreri AJ, Luminari S, Grossi A, Salvi F, Zambello R, Goldaniga M, Volpetti S, and Fanin R

Subjects
Adult, Aged, Aged, 80 and over, Bendamustine Hydrochloride, Female, Follow-Up Studies, Humans, Leukemia, Large Granular Lymphocytic diagnosis, Leukemia, Large Granular Lymphocytic drug therapy, Leukemia, Large Granular Lymphocytic epidemiology, Lymphoma, T-Cell epidemiology, Male, Middle Aged, Retrospective Studies, Antineoplastic Agents, Alkylating therapeutic use, Lymphoma, T-Cell diagnosis, Lymphoma, T-Cell drug therapy, Nitrogen Mustard Compounds therapeutic use, Salvage Therapy methods
Abstract

Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results